Product News: DiaSorin Launches the First CLIA Test Available in the World for the Determination of the 1.25 Vitamin D on its LIAISON XL

05 Jun 2014

The new DiaSorin LIAISON XL assay is the first fully automated 1,25 Dihydroxyvitamin D assay

DiaSorin is proud to announce the launch of its novel 1,25 Vitamin D assay for the quantitative determination of 1,25 Dihydroxyvitamin D levels in human serum and plasma, available on the LIAISON XL analyzer for the market outside the US only.

The new DiaSorin 1,25 Vitamin D is the only product available in the world on the CLIA technology and represents a further milestone of the Group in the bone and mineral clinical area.

The 1,25 Dihydroxyvitamin D is the biological active form of Vitamin D and it is a test run by the same laboratories already performing the Vitamin D 25 OH test where DiaSorin is the undisputed leader in the world.

Mr. Chen Even, Senior Corporate VP Commercial Operations of the DiaSorin Group, commented: “The 1,25 Dihydroxyvitamin D testing volume is between 10% and 15% of the current Vitamin D market, which is above 115 million of Euro in Europe and it’s growing double digit. We want to consistently address this market leveraging on our strong positioning on the Vitamin D franchise thanks to the quality of our products and the continuous success of our LIAISON XL. By year end we also expect to receive the approval for the test in the US market”.

Low levels of Vitamin D can be correlated with various clinical conditions, such as chronic kidney disease, rickets type 1, and hypoparathyroidism, while high levels can be found in rickets type 2, sarcoidosis, reumathoid arthritis, IBD, and primary hyperparathyroidism.

The DiaSorin LIAISON XL assay is the first fully automated 1,25 Dihydroxyvitamin D assay available today. Until now 1,25 Dihydroxyvitamin D assays have required a challenging manual, time consuming, operator dependent up-front extraction step in order to isolate the 1,25 Dihydroxyvitamin D.

The novel LIAISON XL method does not require the sample pre-treatment, offering higher efficiency and quality of the results in just 65 minutes.

With its analytical excellence, the novel assay will enhance DiaSorin’s unique LIAISON Bone and Mineral menu, which today includes 25-OH Vitamin D TOTAL Assay, N-TACT Gen II, 1-84 PTH, BAP OSTASE and Osteocalcin, providing convenience and accuracy of results.

Carlo Rosa, CEO of DiaSorin Group, commented: ”Our new 1,25 Vitamin D on the LIAISON XL is a true game changer in laboratory efficiency. This new product represents our capability in being always innovative and developing products that our clients really need.

We believe the new 1,25 Vitamin D is a breakthrough and we consider it as the first test of a new set of products that the Group is developing for the future, leveraging on the same raw materials of the test launched today”.